NCT00006006View on ClinicalTrials.gov

Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 31, 2000

Primary Completion Date

March 31, 2005

Conditions
Liver Cancer
Interventions
BIOLOGICAL

recombinant interferon alfa

DRUG

thalidomide

Trial Locations (2)

10016

NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York

10029

Mount Sinai School of Medicine, New York

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00006006 - Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed | Biotech Hunter | Biotech Hunter